Neuberger Berman Group LLC Increases Stock Position in DaVita Inc. $DVA

Key Points

• Neuberger Berman Group LLC significantly increased its stake in DaVita Inc. by acquiring an additional 57,027 shares, raising its total ownership to 65,364 shares, valued at approximately $9,999,000.
• Institutional investors dominate DaVita's shareholder base, owning 90.12% of the company, with significant new investments from Epoch Investment Partners and GAMMA Investing LLC.
• Analysts have mixed views on DaVita's stock, with Truist Financial setting a price target of $148.00 and Barclays lowering theirs from $169.00 to $160.00.

Neuberger Berman Group LLC grew its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 684.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,364 shares of the company's stock after acquiring an additional 57,027 shares during the quarter. Neuberger Berman Group LLC owned about 0.09% of DaVita worth $9,999,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of DVA. Epoch Investment Partners Inc. acquired a new stake in DaVita in the 4th quarter valued at approximately $55,100,000. Iron Triangle Partners LP acquired a new position in shares of DaVita in the 4th quarter worth approximately $38,946,000. GAMMA Investing LLC increased its holdings in DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock valued at $35,919,000 after purchasing an additional 233,222 shares in the last quarter. Nuveen LLC acquired a new stake in shares of DaVita in the 1st quarter valued at $20,218,000. Finally, Rovin Capital UT ADV bought a new position in DaVita during the first quarter worth about $18,442,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company's stock.

DaVita Stock Performance

DVA stock traded up $2.8950 during midday trading on Tuesday, reaching $136.1450. 332,106 shares of the company's stock traded hands, compared to its average volume of 863,442. The stock's 50-day moving average is $139.60 and its 200 day moving average is $144.76. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The stock has a market cap of $9.73 billion, a P/E ratio of 13.38, a PEG ratio of 0.97 and a beta of 1.09. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business's revenue was up 6.1% on a year-over-year basis. During the same period last year, the company posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent analyst reports. Barclays lowered their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $164.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.